METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)

HeroBanner_Image
HeroBanner_Image
HeroBanner_Image

The problem, the consequences, and rapid testing solutions

Worldwide, it is estimated that between 2-53 million people carry Methicillin-resistant Staphylococcus aureus (MRSA) and rates are increasing rapidly. This makes MRSA the most commonly identified, antibiotic-resistant pathogen in Europe, the Americas, North Africa, the Middle East and Asia.1

THE PROBLEM

Patients infected with multi-drug resistant organisms such as MRSA are likely to have longer and more expensive hospital stays, and may be more likely to die as a result of the infection.2 MRSA is problematic in healthcare facilities where patients with open wounds, invasive devices and weakened immune systems are at greater risk of infection than the general public.

THE CONSEQUENCES

The multi-drug resistance capability of MRSA means there are limited treatment options and Vancomycin is often the last line of defense against the infection.

Continued inappropriate use and overuse of Vancomycin makes it inevitable that resistance will emerge, and Vancomycin-resistant MRSA has been reported in some countries.3

MRSA img

RAPID TESTING

It is essential that MRSA infections are identified as early as possible and steps are taken to ensure the correct treatment is implemented. Rapid MRSA testing aids in reducing the empirical use of Vancomycin and permits cost-effective decisions for optimal patient management.4

c-reactive-protein img

The Clearview™ PBP2a SA Culture Colony Test is a rapid immuno-chromatographic assay that uses monoclonal antibodies to assist in the detection of MRSA directly from bacterial isolates in five minutes. In a U.S. study, results were available at least one day sooner than standard antimicrobial susceptibility tests, and were used to effectively modify and improve treatment regimens for patients with S. aureus infections .5

View References

  1. Grundmann, H. et al. (2006) Emergence and resurgence of methicillin-resistant Staphylococcus aureus. The Lancet, Vol.368, pp.874-85 [Online] DOI:10.1016/S0140-6736(06)68853-3
  2. Centers for Disease Control and Prevention (CDC) (2012) About Antimicrobial Resistance: A Brief Overview. [Online]. Available at: http://www.cdc.gov/drugresistance/about.html (Accessed: 13 Feb 2013)
  3. Howden, B.P. et al. (2010) Reduced Vanocmycin Susceptibility in Staphylococcus aureus including Vancomycin-intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications. Clinical Microbiology Reviews, 23(1)99 [Online] DOI: 10.1128/CMR.00042-09
  4. Lodise, T.P. and McKinnon, P.S. (2005) Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagnostic Microbiology and Infectious Disease, Vol.52, pp.113-122 [Online] doi:10.1016/j.diagmicrobio.2005.02.007
  5. Barrett, H.L., Trienski, T.L. and DiPersio, J.R. (2012) Laboratory use of a rapid PBP2a immunochromatographic assay: Efficacy and clinical impact. American Society of Microbiology 2012
Sign up for our newsletter to stay up to date with the latest information on antimicrobial resistance
SIGN UP

© 2023 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. Products available in select markets only.

This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.

Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. The companies, websites, products and services, and brands referenced and linked to from this website are not sponsored or endorsed by, or otherwise affiliated with, Abbott or TestTargetTreat.com. GDPR Statement. Interest-Based Ads.

The third-party trademarks, products and services referenced and linked to from this website are included for informational purposes only, and have not been tested or approved by Abbott or TestTargetTreat.com. Neither Abbott nor TestTargetTreat.com make any representations or warranties regarding third-party products or services, and shall not be liable for any claims arising from those products or services or your use thereof. See the Website Terms and Conditions for additional details.

Please click "Accept Sale/Sharing and Targeted Advertising" to enable full site functionality.

At this time, we are experiencing problems with broken links on our site. As an interim solution, for full site functionality you must enable functional and advertising cookies. If you continue to opt-out of these cookies, some content on our site may not be viewable.

We use functional cookies to analyze your use of the site, improve performance and provide a better customer experience. We use advertising cookies to allow us, through certain data assigned and obtained from the user's device, to store or share with third parties information related to user's browsing activity in our website, in order to create an advertising profile and place relevant advertising in our website or those third parties websites. For more information about how Abbott uses cookies please see our Cookie Policy and Privacy Policy.

In order to accept functional and advertising cookies, please click "Enable Cookies" and then click "Accept Sale/Sharing and Targeted Advertising" to view the full site.

COLLAPSE
Learn more about cookies